文献速递药疹与重症皮肤不良反应

欧洲多中心研究:SJS/TEN治疗方式与结局评估

Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study.
PubMed 文献 · JAMA Dermatol · 2021-01-01

该回顾性多中心队列纳入212例SJS/TEN成人患者,描述欧洲治疗差异及6周结局。最常见可疑药物为抗生素,38.2%仅支持治疗;6周死亡率20.8%。最大体表面积剥脱≥30%与严重急性期并发症独立相关,SCORTEN≥2与死亡率显著相关。环孢素与急性期剥脱面积增加≥20%及感染风险升高相关;系统糖皮质激素和静脉免疫球蛋白与感染风险降低相关;各治疗组6周死亡率无显著差异。

要点

  • 最大体表面积剥脱≥30%与严重急性期并发症独立相关(OR 2.49)。
  • SCORTEN≥2与6周死亡率显著相关(OR 10.30)。
  • 各治疗组6周死亡率无显著差异,需前瞻性研究。

核心结论

  • 欧洲SJS/TEN治疗策略存在差异,各治疗组6周死亡率无显著差异,提示需开展前瞻性治疗研究并建立登记系统。

研究设计与样本

  • 回顾性泛欧洲多中心队列研究,纳入13个ToxiTEN ERN-skin转诊中心,2015年1月1日至2019年12月31日共212例成人SJS/TEN患者,随访6周。

主要发现

  • 212例患者中女性134/211(63.7%),平均(SD)年龄51.0(19.3)岁,平均(SD)体表面积剥脱27%(32.8%)。
  • 176例(83.0%)识别出可疑药物,最常见为抗生素(21.2%)、抗惊厥药(18.9%)、非甾体抗炎药(11.8%)、别嘌醇(11.3%)和磺胺类(10.4%)。
  • 治疗方式包括仅最佳支持治疗(38.2%)、系统糖皮质激素(35.4%)、静脉免疫球蛋白(23.6%)、环孢素(10.4%)和抗TNF药物(3.3%)。
  • 63.7%患者发生严重急性期并发症,6周死亡率为20.8%。

关键数值与推荐

  • 各治疗组间6周死亡率无显著差异。

临床怎么用

  • 对SJS/TEN患者应评估最大体表面积剥脱和SCORTEN以分层严重急性期并发症及死亡风险。
  • 选择环孢素时需警惕体表面积剥脱增加和感染风险升高。
  • 系统糖皮质激素或静脉免疫球蛋白可能降低感染风险,但需结合个体情况权衡。

局限性

  • 回顾性设计可能引入选择偏倚和信息偏倚。
  • 各治疗组间样本量和基线特征差异可能影响比较。
  • 随访时间仅6周,未评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug reactions associated with a high rate of mortality and morbidity. There is no consensus on the treatment strategy. OBJECTIVE: To explore treatment approaches across Europe and outcomes associated with the SJS/TEN disease course, as well as risk factors and culprit drugs. DESIGN, SETTING, AND PARTICIPANTS: A retrospective pan-European multicenter cohort study including 13 referral centers belonging to the ToxiTEN ERN-skin subgroup was conducted. A total of 212 adults with SJS/TEN were included between January 1, 2015, and December 31, 2019, and data were collected from a follow-up period of 6 weeks. MAIN OUTCOMES AND MEASURES: Risk factors for severe acute-phase complications (acute kidney failure, septicemia, and need for mechanical ventilation) and mortality 6 weeks following admission were evaluated using a multivariable-adjusted logistic regression model. One tool used in evaluation of severity was the Score of Toxic Epidermal Necrolysis (SCORTEN), which ranges from 0 to 7, with 7 the highest level of severity. RESULTS: Of 212 patients (134 of 211 [63.7%] women; mean [SD] age, 51.0 [19.3] years), the mean (SD) body surface area detachment was 27% (32.8%). In 176 (83.0%) patients, a culprit drug was identified. Antibiotics (21.2%), followed by anticonvulsants (18.9%), nonsteroidal anti-inflammatory drugs (11.8%), allopurinol (11.3%), and sulfonamides (10.4%), were the most common suspected agents. Treatment approaches ranged from best supportive care only (38.2%) to systemic glucocorticoids (35.4%), intravenous immunoglobulins (23.6%), cyclosporine (10.4%), and antitumor necrosis factor agents (3.3%). Most patients (63.7%) developed severe acute-phase complications. The 6-week mortality rate was 20.8%. Maximal body surface area detachment (≥30%) was found to be independently associated with severe acute-phase complications (fully adjusted odds ratio [OR], 2.49; 95% CI, 1.21-5.12; P = .01) and SCORTEN greater than or equal to 2 was significantly associated with mortality (fully adjusted OR, 10.30; 95% CI, 3.82-27.78; P < .001). Cyclosporine was associated with a higher frequency of greater than or equal to 20% increase in body surface area detachment in the acute phase (adjusted OR, 3.44; 95% CI, 1.12-10.52; P = .03) and an increased risk of infections (adjusted OR, 7.16; 95% CI, 1.52-33.74; P = .01). Systemic glucocorticoids and intravenous immunoglobulins were associated with a decreased risk of infections (adjusted OR, 0.40; 95% CI, 0.18-0.88; P = .02). No significant difference in 6-week mortality was found between treatment groups. CONCLUSIONS AND RELEVANCE: This cohort study noted differences in treatment strategies for SJS/TEN in Europe; the findings suggest the need for prospective therapeutic studies to be conducted and registries to be developed.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Brüggen MC, Chua SL, et al. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study. JAMA Dermatol. 2021. PMID: 34431984. doi:10.1001/jamadermatol.2021.3154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。